ASCO 2016 | Safety and efficacy of single agent rovalpituzumab tesirine in small cell lung cancer (SCLC)
Press brief by Charles Rudin, MD, PhD of the Memorial Sloan Kettering Cancer Center, New York, NY, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.
Get great new content delivered to your inboxSign up
Accelerate, Coordinate, Evaluate (ACE) cancer care: the CRUK programme streamlining the care pathway
Lung cancer screening in the UK: CRUK, UK NSC, Public Health England & NHS England
The Recovery Package in lung cancer
Single-port VATS for NSCLC: outcomes related to smoking status
Psychological impact of lung cancer screening
Mamta Ruparel et al.
More from Charles Rudin